spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  bone loss 

 HSMN NewsFeed - 16 May 2024
FX Shoulder Solutions, Inc. Receives FDA 510k Clearance for Full-Wedge Augmented Glenoid Baseplates
Devices Orthopaedic FDA
 HSMN NewsFeed - 9 Dec 2021
Richter and Hikma sign exclusive commercialisation and license agreement for denosumab in the US, a proposed biosimilar referencing Prolia(R) and Xgeva(R)
Biopharmaceuticals Generics Licensing
 HSMN NewsFeed - 18 Aug 2021
DePuy Synthes Introduces the INHANCE(TM) Shoulder System, a First-to-Market, Fully Integrated Shoulder Arthroplasty System
Devices Orthopaedic Product Launch
 HSMN NewsFeed - 12 Dec 2019
European Commission Approves EVENITY(R) (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Oct 2019
EVENITY(R) (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Sep 2019
Arthrosurface Receives FDA Clearance for BOSS(TM) Toe Fixation System
Devices Orthopaedic FDA
 HSMN NewsFeed - 19 Feb 2019
NuVasive's Proprietary Magnetic Implant System To Be Used In First-Of-Its-Kind, All-Internal Bone Transport System
Devices Orthopaedic FDA Regulatory
 HSMN NewsFeed - 24 Jul 2018
AbbVie Receives U.S. FDA Approval of ORILISSA(TM) (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 20 Jun 2018
Medtronic Announces Second Bone Cement Solution Indicated for Treating Sacral Fractures
Devices Interventional Radiology Orthopaedic FDA
 HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Apr 2018
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia(R) (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Oct 2017
NuVasive Receives Expanded FDA 510(k) Clearance For Innovative Magnetic Limb Lengthening Technology
Devices Orthopaedic FDA
 HSMN NewsFeed - 6 Jun 2017
100,000th Robotic-Arm Assisted Joint Replacement Procedure Performed in the U.S. with Stryker's Mako System
Devices Orthopaedic
 HSMN NewsFeed - 22 May 2017
BONESUPPORT Announces First Patient Enrolled in FORTIFY Trial With CERAMENT G, a Novel Injectable, Antibiotic-eluting Bone Graft Substitute
Devices Orthopaedic
 HSMN NewsFeed - 31 Oct 2016
Onkos Surgical(TM) Receives FDA 510(k) Clearance for ELEOS(TM) Limb Salvage System
Devices Oncology Surgery FDA
 HSMN NewsFeed - 23 Nov 2015
ObsEva Closes CHF 60 (USD 60) Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Mar 2014
Freedom Knee(R) Revision Knee System Receives US FDA 510(k) Clearance Ahead of American Academy of Orthopaedic Surgeons (AAOS) Meeting
Devices Orthopaedic FDA
 HSMN NewsFeed - 3 Oct 2013
Pfizer Inc. Announces FDA Approval of DUAVEE(TM) (conjugated estrogens/ bazedoxifene) for the Treatment of Moderate-to-Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause and the Prevention of Postmenopausal Osteoporosis [1]
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Mar 2013
Misonix BoneScalpel(TM) Subject of New Clinical Paper Focused on Spine Surgery
Devices Orthopaedic Neurosurgery
 HSMN NewsFeed - 8 Nov 2012
Angel(R) cPRP System Granted FDA 510(K) Clearance for Processing Blood and Bone Marrow Aspirate
Devices Regenerative Medicine Orthopaedic FDA
 HSMN NewsFeed - 24 Apr 2012
Genta Appoints Dr. Brian Leyland-Jones and Richard J. Moran to Its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Jan 2012
Biomet Receives FDA Clearance for Two New Products: E1(R) Humeral Bearing for the Comprehensive(R) Reverse Shoulder System and the Comprehensive(R) Segmental Revision System
Devices Orthopaedic FDA
 HSMN NewsFeed - 30 Nov 2011
Abbott Receives FDA Clearance for New Test to Detect Vitamin D Levels
Diagnostics FDA
 HSMN NewsFeed - 19 Sep 2011
FDA Approves New Indications for Prolia(R) (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Sep 2011
Medtronic Announces Launch of ARTISAN(TM) Space Maintenance System
Devices Orthopaedic
 HSMN NewsFeed - 13 Dec 2010
Ascension Orthopedics Implants PyroTITAN in France
Devices Orthopaedic
 HSMN NewsFeed - 7 Sep 2010
Alethia Biotherapeutics Secures C$9.6 Million in Series A Financing to Fund Its Therapeutic Monoclonal Antibody Product Pipeline
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 Aug 2010
Axxess Pharma, Inc. Signs Exclusive License Agreement to Globally Market and Distribute High Potency Vitamin D-3 to Help Reduce Bone Loss and Joint Pain
Biopharmaceuticals Licensing
 HSMN NewsFeed - 16 Jun 2010
Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
Biopharmaceuticals
 HSMN NewsFeed - 28 May 2010
Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Apr 2010
Genta's Tesetaxel Granted Fast Track Designation by FDA for Advanced Gastric Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Apr 2010
DFine Inc Launches Next Generation Access System for RF Kyphoplasty
Devices Orthopaedic Neurosurgery
 HSMN NewsFeed - 20 Feb 2010
FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Feb 2010
Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2009
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Nov 2009
Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Oct 2009
Genta Announces Top-Line Results of AGENDA Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Oct 2009
Amgen Provides Update on Status of Prolia(TM) (Denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Sep 2009
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Sep 2009
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Sep 2009
Wyeth Presents Data from Five-Year Vertebral Fracture Prevention Study with Bazedoxifene
Biopharmaceuticals
 HSMN NewsFeed - 27 Jul 2009
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Biopharmaceuticals
 HSMN NewsFeed - 20 Jul 2009
Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study
Devices Orthopaedic
 HSMN NewsFeed - 1 Jun 2009
FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Apr 2009
Ligand Announces Approval in Europe of CONBRIZA for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Apr 2009
First Ever Prospective Fracture Study in Prostate Cancer Patients on ADT Reveals These Men Are at High Risk for Skeletal Fractures
Biopharmaceuticals Oncology Urology
 HSMN NewsFeed - 7 Mar 2009
FDA Appeal Decision Indicates that Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Trial
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Feb 2009
Genta Submits Randomized Study of Tesetaxel in Patients with Advanced Gastric Cancer to FDA for Special Protocol Assessment
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Dec 2008
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer
Biopharmaceuticals
 HSMN NewsFeed - 25 Sep 2008
Merck & Co., Inc. and Japan Tobacco Inc. Sign Licensing Agreement for Novel Osteoanabolic Drug Candidate to Treat Osteoporosis
Biopharmaceuticals Licensing
 HSMN NewsFeed - 15 Sep 2008
Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate
Biopharmaceuticals
 HSMN NewsFeed - 25 Jul 2008
Amgen Announces Positive Top-Line Results for Denosumab Pivotal Postmenopausal Osteoporosis Trial
Biopharmaceuticals
 HSMN NewsFeed - 14 Jul 2008
Amgen Announces Positive Top-Line Results for Denosumab Treatment of Bone Loss in Men With Non-Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jun 2008
Odanacatib, an Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2008
Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 May 2008
Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial versus Weekly Alendronate (FOSAMAX(R))
Biopharmaceuticals
 HSMN NewsFeed - 27 May 2008
Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2008
Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 May 2008
Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study
Biopharmaceuticals
 HSMN NewsFeed - 6 May 2008
GTx Appoints Kenneth S. Robinson, MD to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Apr 2008
Pivotal Phase 3 Data Show Denosumab Increased Bone Density at Multiple Skeletal Sites in Early and Later Stage Postmenopausal Women
Biopharmaceuticals
 HSMN NewsFeed - 2 Apr 2008
Genta Restructures Operations to Focus on Priority Initiatives
Biopharmaceuticals
 HSMN NewsFeed - 17 Mar 2008
FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Mar 2008
Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 3 Mar 2008
GTx Announces Additional Top Line Phase III Data Demonstrating Toremifene Citrate 80 mg Reduced Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Feb 2008
GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostate Cancer Patients on Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2008
Genta Announces Senior Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jan 2008
Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Jan 2008
Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R))
Biopharmaceuticals
 HSMN NewsFeed - 24 Dec 2007
Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Dec 2007
Hollis-Eden Pharmaceuticals Announces Cystic Fibrosis Foundation Therapeutics Selects TRIOLEX(TM) (HE3286) as a Next-Generation Oral Anti-Inflammatory Drug Candidate
Biopharmaceuticals
 HSMN NewsFeed - 15 Dec 2007
New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Dec 2007
Anastrozole Confirmed Superior in Breast Cancer Prevention
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Dec 2007
Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2007
FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2007
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Nov 2007
Bentley Announces Its First Product Approval in France
Biopharmaceuticals Generics Regulatory
 HSMN NewsFeed - 30 Oct 2007
Acceleron Pharma Completes $31M Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 29 Oct 2007
Bentley Announces Product Approvals in Spain and Ireland
Biopharmaceuticals Generics Regulatory
 HSMN NewsFeed - 26 Oct 2007
Genta Announces Resignation of Dr. Betsy McCaughey from Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Oct 2007
Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Oct 2007
Alethia Biotherapeutics Inc. Announces in-Licensing of Family of Monoclonal Antibodies to Treat Metastatic Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 24 Sep 2007
Acceleron Pharma Appoints Niels Borgstein, M.D. as Vice President, Medical Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2007
Acceleron Pharma Appoints John L. Knopf, Ph.D., as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2007
First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
Biopharmaceuticals
 HSMN NewsFeed - 1 Aug 2007
Genta and Emisphere Technologies File IND with FDA for Oral Drug to Treat Bone Disease
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 16 Jul 2007
Bentley Announces Product Approvals for Generic Pharmaceuticals
Biopharmaceuticals Generics Regulatory
 HSMN NewsFeed - 12 Jul 2007
GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2007
Amgen Names David Lacey, M.D., Senior Vice President, Head of Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 May 2007
Portland Orthopaedics resumes control of US hip distribution
Devices Orthopaedic Distribution
 HSMN NewsFeed - 25 Apr 2007
Acceleron Pharma Appoints James Desiderio, Ph.D. as Vice President, Program Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Apr 2007
Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Apr 2007
GTx Announces Ostarine(TM) Improved Insulin Resistance among Elderly Patients in a Recently Completed Phase II Clinical Trial
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 10 Apr 2007
GTx, Inc. Appoints Jeff Hesselberg as Vice President of Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Apr 2007
GTx, Inc. Appoints Ronald A. Morton, Jr. MD, FACS as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Apr 2007
Osteologix Appoints Philip J. Young President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Mar 2007
Acceleron Pharma Appoints Robert Steininger as Senior Vice President, Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Feb 2007
Initiation of Phase III Program Using Emisphere's eligen(R) Technology for Oral Salmon Calcitonin
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 23 Feb 2007
GTx's ACAPODENE Interim Bone Mineral Density and Lipid Data Highlighted at Press Briefing at Prostate Cancer Symposium of the American Society of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2007
GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jan 2007
BioMimetic Therapeutics Reports Positive Clinical Results Using GEM OS(R)1 to Treat Distal Radius Fractures
Devices Orthopaedic
 HSMN NewsFeed - 15 Jan 2007
Portland Orthopaedics’ Equator Plus Cup Launched in US
Devices Orthopaedic
 HSMN NewsFeed - 8 Jan 2007
Neurocrine Biosciences Announces Positive Results From Second Phase II Study With Its Orally Active GnRH Receptor Antagonist in Endometriosis
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2006
Repros Reports Proellex Achieves Statistically Significant Pain Reduction in Endometriosis Trial
Biopharmaceuticals
 HSMN NewsFeed - 17 Nov 2006
Celtic Pharma and Neurobiological Technologies Present an Update on XERECEPT(R) for Peritumoral Brain Edema at the 11th Annual Meeting of the Society for Neuro-Oncology
Biopharmaceuticals Oncology Neurology
 HSMN NewsFeed - 24 Oct 2006
Repros Reports Partial Interim Assessment of Phase 2 Study of Proellex(TM) in Endometriosis
Biopharmaceuticals
 HSMN NewsFeed - 19 Sep 2006
Higher Persistency Rates Seen with FOSAMAX(R) Once Weekly Therapies Compared to Other Weekly and Monthly Oral Bisphosphonates, According to Two New Outcomes Studies
Biopharmaceuticals
 HSMN NewsFeed - 7 Sep 2006
GTx and Ipsen Enter Into Partnership Agreement for the European Rights of Acapodene(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 7 Sep 2006
Ipsen and GTx Enter into Partnership Agreement for The European Rights of Acapodene(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 22 Jun 2006
In a Phase III Lipid Interim Analysis, ACAPODENE Treatment Lowered Cholesterol and Raised HDL In Prostate Cancer Patients On Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2006
Nexa Orthopedics Receives FDA Clearance to Market Pyrolytic Carbon Implant
Devices Orthopaedic FDA
 HSMN NewsFeed - 8 May 2006
Wyeth Comments on New Report From The Nurses' Health Study Published Today in the Archives of Internal Medicine
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 63

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 63 additional stories matching:
bone loss
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.